Public Information Campaign
Underway for Developer of Synthetic
Blood Substitute
PASADENA, Calif.--(BUSINESS WIRE)--Aug. 26, 1998--Dr. Thomas C. Drees, president and
chief executive officer of Sanguine Corp. (OTC BB:SGNC), Wednesday announced the launch of a
public information campaign to inform the public about the worldwide need for a blood substitute, and
the company's own collaborative research with Battelle Memorial Research Institute to develop a viable
synthetic blood product.
Salt Lake City-based Smith Consulting Services (SCS), one of Sanguine's principal shareholders, has
retained mkl/public relations (mkl/pr) as agency of record to develop the campaign and to update
investors and shareholders on current activity and progress.
According to Mary Kay Lazarus, mkl/pr president, the agency welcomes the assignment to increase
awareness of the significant worldwide blood supply shortages as well as the growing risk of
blood-borne diseases.
''Dr. Drees' leadership in more than 20 years of blood substitute research and in the development of the
only blood substitute to gain FDA approval provide significant opportunity for public dialogue about this
critical issue and the significance of Sanguine's research,'' commented Lazarus.
The PR agency specializes in national and international business press and media coverage; mkl/pr
clients include ASARCO, EURO RSCG/DSW Partners, Iomega, and First Security Bank.
|
